NEW YORK (Reuters Health)—Results of a randomized controlled trial do not support routine use of proactive therapeutic drug monitoring (TDM) during infliximab induction for improving disease remission rates in patients rheumatoid arthritis (RA) and other chronic immune-mediated inflammatory diseases. Proactive therapeutic drug monitoring tailors biologic therapy to individual patients by measuring serum drug levels and…
Search results for: Primary care

10 Tips to Master E/M Coding Changes
Learn to properly use the revised CPT codes to document your time and medical decision making during patient visits to help ensure your practice is appropriately remunerated.

FDA Approves Belimumab & Voclosporin for Lupus Nephritis
In December, the FDA approved belimumab, the first drug approved to treat lupus nephritis, an historic action that was rapidly followed in January by the approval of a second treatment for lupus nephritis, voclosporin.

Spring 2021’s Awards, Appointments & Announcements in Rheumatology
Leigh Callahan, PhD, Now President Elect of United States Bone & Joint Initiative After 20 years of involvement with the U.S. Bone and Joint Initiative (USBJI), Leigh F. Callahan, PhD, Mary Link Briggs Distinguished Professor of Medicine, associate director, Thurston Arthritis Research Center, and director, Osteoarthritis Action Alliance at the University of North Carolina at…

Study Suggests Genetics Play Strong Role in Young Fibromyalgia Patients
Younger individuals (<50 years) have a stronger genetic component in their fibromyalgia score than older individuals (>60 years), according to a study published in Arthritis & Rheumatology.1 Studies that suggest a strong familial component to fibromyalgia have often focused on individuals with primary fibromyalgia who did not have another accompanying disorder, the study authors report….

Case Report: Evans Syndrome in Lupus
Rheumatologists are in the unique position of diagnosing and treating rare auto-inflammatory and autoimmune diseases. Although systemic lupus erythematosus (SLE) often has textbook presentations, it is a heterogeneous condition with a wide variety of disease manifestations. In 2019, the European League Against Rheumatism and the ACR introduced new classification criteria to help diagnose this condition.1…

How to Improve Oral & Eye Health in Sjögren’s Patients
ACR CONVERGENCE 2020—Sjögren’s syndrome requires care from several specialists, and presenters at the Sjögren’s Syndrome: Dental and Ocular Perspectives session shared diagnostic and treatment pearls from their respective specialties. Rebecca Manno, MD, MHS, of the Comprehensive Arthritis and Rheumatology Center of the U.S. Virgin Islands moderated the session. Oral Health Dry mouth is famously associated…

Study Finds NSAIDs Raise Heart Disease Risk in Osteoarthritis Patients
In a controlled, large-cohort, longitudinal study from Canada, Atiquazzaman et al. found that use of non-steroidal anti-inflammatory drugs (NSAIDs) substantially contributes to increased cardiovascular disease risk among people with osteoarthritis (OA).1 This is the first study to evaluate the mediating role that NSAIDs play in the association between OA and cardiovascular disease (CVD), and the…

Late-Breaking Abstract Session Spans the Realm of Drug-Related Research
In the late-breaking abstract session at ACR Convergence 2020, drug research for a variety of indications is reviewed.
What to Expect in State Legislatures in 2021
New state legislatures face many continuing issues, including budget shortfalls, vaccine distribution problems and strained healthcare infrastructure. However, opportunities exist for significant policy wins for rheumatology, particularly on the issues of step therapy reform, telemedicine and copay accumulators.
- « Previous Page
- 1
- …
- 81
- 82
- 83
- 84
- 85
- …
- 137
- Next Page »